Gubra Reports Q3 2026 Results, Narrows CRO Guidance
Gubra reported USD 50 million and EUR 10 million in partner milestones contributing to record-level earnings. CRO revenue grew 6% with a 25% EBIT margin; full-year CRO guidance was narrowed to 2—6% growth and a 10—13% margin. Two partnered obesity programs advanced to Phase 2, and GUB-UCN2 entered Phase 1/2a testing.
Gubra A/S announced its Q3 2026 financial results, highlighted by USD 50 million and EUR 10 million in partner milestones that contributed to record-level earnings. The company's contract research organization (CRO) segment saw revenue growth of 6% and an improved EBIT margin of 25%. In its drug discovery pipeline, two partnered obesity programs have advanced to Phase 2, and the GUB-UCN2 program has entered Phase 1/2a clinical testing. Following these results, the company narrowed its full-year 2026 CRO guidance to 2—6% growth with a 10—13% margin and reported a reduction in biotech cost guidance.